Potential for a personalised approach in renal tumours

Post Session 05

**Friday 15 March**

**09:00 - 10:30**

**Location:** Green Area, Room 12

**Chairs:**
- K. Junker, Homburg (DE)
- G. Procopio, Milan (IT)
- G. Stewart, Cambridge (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

---

**Comprehensive molecular and genomic characterization of pancreatic tropism in metastatic renal cell carcinoma**


1University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, 2Cleveland Clinic, Dept. of Internal Medicine, Cleveland, United States of America, 3University of Texas Southwestern Medical Center, Dept. of Internal Medicine, Dallas, United States of America, 4University of Texas Southwestern Medical Center, Dept. of Bioinformatics, Dallas, United States of America, 5University of Texas Southwestern Medical Center, Dept. of Pathology, Dallas, United States of America

Aims and objectives of this presentation

---

**Comprehensive investigation of the molecular underpinnings of translocation renal cell carcinoma**

By: Marcon J. 1, Sanchez A. 1, Gupta S. 2, Di Natale R.G. 1, Sandhu A. 3, Mano R. 1, Silagy A.W. 1, Blum K.A. 1, Nassau D.E. 1, Motzer R.J. 4, Coleman J.A. 1, Russo P. 1, Reuter V.E. 2, Hakimi A.A. 1, Reznik E. 3

1Memorial Sloan-Kettering Cancer Center, Dept. of Surgery, Urology Service, New York, United States of America, 2Memorial Sloan-Kettering Cancer Center, Dept. of Pathology, New York, United States of America, 3Memorial Sloan-Kettering Cancer Center, Computational Biology Center, Center for Molecular Oncology, New York, United States of America, 4Memorial Sloan-Kettering Cancer Center, Genitourinary Oncology Service, Dept. of Medicine, New York, United States of America

Aims and objectives of this presentation
The concordant analysis of target gene sequencing data showing the tumor heterogeneity in triplet-paired metastatic tumor tissues in metastatic renal cell carcinoma

By: Kim S.H. ¹, Park W.S. ², Kim S-H. ¹, Chung J. ³
¹Center for Prostate Cancer, Research Institute and Hospital of National Cancer Center, Dept. of Urology, Goyang, South Korea, ²Center for Prostate Cancer, Research Institute and Hospital of National Cancer Center, Dept. of Pathology, Goyang, South Korea, ³Center for Prostate Cancer, National Cancer Center, Dept. of Urology, Goyang, South Korea

Aims and objectives of this presentation

Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients

By: Singla N. ¹, Woolford L. ², Stevens C. ², Tcheuyap V. ², Onabolu O. ², Xie Z. ³, McKay R. ², Wang T. ³, Christie A. ⁴, Gahan J. ¹, Bagrodia A. ¹, Raj G. ¹, Sagalowsky A. ¹, Lotan Y. ¹, Cadeddu J. ¹, Margulis V. ¹, Kapur P. ⁵, Brugarolas J. ²
¹University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ²University of Texas Southwestern Medical Center, Dept. of Internal Medicine, Dallas, United States of America, ³University of Texas Southwestern Medical Center, Dept. of Bioinformatics, Dallas, United States of America, ⁴University of Texas Southwestern Medical Center, Dept. of Biostatistics, Dallas, United States of America, ⁵University of Texas Southwestern Medical Center, Dept. of Pathology, Dallas, United States of America

Aims and objectives of this presentation

Feasibility of establishing renal cancer patient-specific ‘tumouroids’ as personalised treatment screening tools

By: Stamati K. ¹, Neves J.B. ¹, De Albuquerque Garcia Redondo P. ¹, Presneau N. ², Azimi T. ², Mohammad Hadi L. ¹, Brew-Graves C. ³, Williams N.R. ³, Grierson J. ³, Tran M.G.B. ¹, Cheema U. ⁴, Loizidou M. ¹, Emberton M. ⁵
¹UCL, Research Department of Surgical Biotechnology, Division of Surgery and Interventional Science, London, United Kingdom, ²University of Westminster, Cancer Research Group, London, United Kingdom, ³UCL, Surgical and Interventional Trials Unit, Division of Surgery and Interventional Science, London, United Kingdom, ⁴UCL, Research Department of Orthopaedics and Musculoskeletal Science, Division of Surgery and Interventional Science, London, United Kingdom, ⁵UCL, Faculty of Medical Science, London, United Kingdom

Aims and objectives of this presentation
Improving the definition of high-risk patients for tumor recurrence from clear-cell renal cell carcinoma – The U-CISS classification


1Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, CA - Department of Urology, University Hospital Bicetre, APHP, University Paris-Saclay, Dept. of Urology, Le Kremlin Bicetre, France, 2University Medicine Greifswald, Dept. of Urology, Greifswald, Germany, 3Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Dept. of Urology, Los Angeles, United States of America, 4David Geffen School of Medicine at UCLA, Dept. of Hematology and Oncology, Los Angeles, United States of America, 5Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Dept. of Hematology and Oncology, Los Angeles, United States of America

Aims and objectives of this presentation

Tumor-infiltrating regulatory T lymphocytes orchestrate oncogenic PAK1-conferred immune evasion in clear-cell renal cell carcinoma

By: Qu Y. 1, Liu L. 1, Bai Q. 1, Xu J. 2, Guo J. 1

1Zhongshan Hospital, Fudan University, Dept. of Urology, Shanghai, China, 2Fudan University, Dept. of Biochemistry and Molecular Biology, Shanghai, China

Aims and objectives of this presentation

Individualized immune-related gene signature predicts immune status and oncologic outcomes in clear cell renal cell carcinoma patients

By: Xiong Y., Liu L., Bai Q., Xia Y., Wang J., Guo J.

Zhongshan Hospital, Fudan University, Dept. of Urology, Shanghai, China

Aims and objectives of this presentation

Identification of a microRNA profile in urine with diagnostic and prognostic value for clear cell renal cell carcinoma

By: Oto Martinez J. 1, Solmoirago M.J 1, Pérez-Ardavin J. 2, Sánchez-González J.V 2, Plana E. 3, Hervás D. 4, Fernández-Pardo Á. 1, Yelo M. 1, Vera C.D 2, Martínez-Sarmiento M. 2, España F. 1, Navarro S. 1, Medina P. 1

1Medical Research Institute Hospital La Fe, Dept. of Haemostasis, Thrombosis, Arteriosclerosis and Vascular Biology Research Group, Valencia, Spain, 2La Fe University and Polytechnic Hospital, Dept. of Urology, Valencia, Spain, 3La Fe University and Polytechnic Hospital, Dept. of Angiology and Vascular Surgery Service, Valencia, Spain, 4Medical Research Institute of Hospital La Fe, Biostatistics Unit, Valencia, Spain
Aims and objectives of this presentation
66

Real world data of how next-generation sequencing changes treatment strategy and identify hereditary diseases in urology cancers

By: Wang H-K., Yao Z., Ye D.W.
Shanghai Cancer Center, Dept. of Urology, Shanghai, China

Aims and objectives of this presentation
67

The UCLA histo-genetic risk classification (U-HGRC) to stratify prognosis of localized clear-cell renal cell carcinoma

By: Lebacle C.\textsuperscript{1}, Pooli A.\textsuperscript{2}, Rao N.\textsuperscript{3}, Wood E.L.\textsuperscript{4}, Kroeger N.\textsuperscript{5}, Kim G.\textsuperscript{6}, Faiena I.\textsuperscript{2}, Liu S.T.\textsuperscript{7}, Chami K.\textsuperscript{2}, Beldegrun A.S.\textsuperscript{2}, Shuch B.\textsuperscript{2}, Drakaki A.\textsuperscript{8}, Pantuck A.J.\textsuperscript{2}
\textsuperscript{1}Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, CA - Department of Urology, University Hospital Bicetre, APHP, University Paris-Saclay, Dept. of Urology, Le Kremlin Bicetre, France, \textsuperscript{2}Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Dept. of Urology, Los Angeles, United States of America, \textsuperscript{3}David Geffen School of Medicine at UCLA, Dept. of Pathology and Cytogenetic lab, Los Angeles, United States of America, \textsuperscript{4}David Geffen School of Medicine at UCLA, Dept. of Urology, Los Angeles, United States of America, \textsuperscript{5}University Medicine Greifswald, Dept. of Urology, Greifswald, Germany, \textsuperscript{6}Fielding School of Public Health at UCLA, Los Angeles, CA - Department of Radiological Science, David Geffen School of Medicine at University of California, Dept. of Biostatistics, Los Angeles, United States of America, \textsuperscript{7}David Geffen School of Medicine at UCLA, Dept. of Hematology and Oncology, Los Angeles, United States of America, \textsuperscript{8}Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Dept. of Hematology and Oncology, Los Angeles, United States of America

Aims and objectives of this presentation
69

Genomic categorization of high-grade unclassified renal cell carcinoma to refine prognostication and therapeutic approach

By: Marcon J.\textsuperscript{1}, Jayakumaran G.\textsuperscript{2}, Di Natale R.\textsuperscript{1}, Ghanaat M.\textsuperscript{1}, Brannon R.\textsuperscript{3}, Al-Ahmadie H.\textsuperscript{2}, Fine S.\textsuperscript{2}, Gopalan A.\textsuperscript{2}, Sirinitrapun S.\textsuperscript{2}, Tickoo S.\textsuperscript{2}, Arcila M.\textsuperscript{2}, Motzer R.\textsuperscript{4}, Coleman J.\textsuperscript{1}, Russo P.\textsuperscript{1}, Reuter V.\textsuperscript{2}, Hakimi A.\textsuperscript{1}, Chen Y-B.\textsuperscript{2}
\textsuperscript{1}Memorial Sloan-Kettering Cancer Center, Urology Service, Dept. of Surgery, New York, United States of America, \textsuperscript{2}Memorial Sloan-Kettering Cancer Center, Dept. of Pathology, New York, United States of America, \textsuperscript{3}Memorial Sloan-Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York, United States of America, \textsuperscript{4}Memorial Sloan-Kettering Cancer Center, Genitourinary Oncology Service, Dept. of Medicine, New York, United States of America
Circulating tumor cells in renal cancer

By: Klézl P.¹, Sonsky J.¹, Grill R.¹, Pospisilova E.², Kolostova K.², Bobek V.²
¹University Hospital Kralovske Vinohrady, Dept. of Urology, Prague, Czech Republic,
²University Hospital Kralovske Vinohrady, Dept. of Laboratory Diagnostics, Lab. Genetics, Prague, Czech Republic